This Project Grant award of $613,585.00 from the Defense Health Agency (DHA) supports research by James Cook University's Australian Institute of Tropical Health and Medicine to develop point-of-injury intranasal drug therapies to reduce secondary injury and improve outcomes for individuals with traumatic brain injuries (TBIs) in civilian and military resource-limited environments. This research falls under the DHA's Military Medical Research and Development program (CFDA 12.420), which focuses on transforming healthcare for Service Members and the public through innovative medical solutions for the battlefield. The award will fund the development of these intranasal drug therapies over a 3-year period from September 1, 2023 to August 31, 2026.
Generated 5/14/24, 7:35 AM